美诺华上涨5.02%，报24.89元/股

Core Viewpoint - Meinuo Pharma's stock price increased by 5.02% on August 8, reaching 24.89 CNY per share, with a trading volume of 311 million CNY and a market capitalization of 5.472 billion CNY, indicating positive market sentiment towards the company [1]. Group 1: Company Overview - Meinuo Pharma is located in Ningbo High-tech Zone and specializes in the research, production, and sales of specialty APIs (including intermediates) and finished drugs [1]. - The company is one of the largest exporters of specialty APIs to Europe in China, with products covering cardiovascular, central nervous system, and gastrointestinal treatment areas [1]. - Since its listing, the company has adhered to a growth strategy of "internal growth + external expansion," focusing on continuous R&D innovation and business development [1]. Group 2: Financial Performance - As of March 31, Meinuo Pharma had 27,600 shareholders, with an average of 7,720 circulating shares per person [2]. - For the first quarter of 2025, the company achieved a revenue of 276 million CNY, representing a year-on-year growth of 5.22% [2]. - The net profit attributable to shareholders for the same period was 21.22 million CNY, showing a significant year-on-year increase of 51.12% [2].